Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy

Martin, Jocelyne; Ginsberg, Robert J.; Abolhoda, Amir; Bains, Manjit S.; Downey, Robert J.; Korst, Robert J.; Weigel, Tracey L.; Kris, Mark G.; Venkatraman, Ennapadam; Rusch, Valerie W.

doi:10.1016/s0003-4975(01)02995-2

Cited by 289 publications

(197 citation statements)

References 18 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…Mortality can be even higher when associated with preoperative chemotherapy (3). The combination with other procedures such as extrapleural pneumonectomy is associated with a mortality rate of 4 to 7% (4,5).…”

Section: Introductionmentioning

confidence: 99%

Effects of pneumonectomy on nitric oxide synthase expression and perivascular edema in the remaining lung of rats

Samano

Pazetti

Prado

et al. 2009

Braz J Med Biol Res

View full text Add to dashboard Cite

Pneumonectomy is associated with high mortality and high rates of complications. Postpneumonectomy pulmonary edema is one of the leading causes of mortality. Little is known about its etiologic factors and its association with the inflammatory process. The purpose of the present study was to evaluate the role of pneumonectomy as a cause of pulmonary edema and its association with gas exchange, inflammation, nitric oxide synthase (NOS) expression and vasoconstriction. Forty-two non-specific pathogen-free Wistar rats were included in the study. Eleven animals died during or after the procedure, 21 were submitted to left pneumonectomy and 10 to sham operation. These animals were sacrificed after 48 or 72 h. Perivascular pulmonary edema was more intense in pneumonectomized rats at 72 h (P = 0.0131). Neutrophil density was lower after pneumonectomy in both groups (P = 0.0168). There was higher immunohistochemical expression of eNOS in the pneumonectomy group (P = 0.0208), but no statistically significant difference in the expression of iNOS. The lumen-wall ratio and pO2/FiO2 ratio did not differ between the operated and sham groups after pneumonectomy. Left pneumonectomy caused perivascular pulmonary edema with no elevation of immunohistochemical expression of iNOS or neutrophil density, suggesting the absence of correlation with the inflammatory process or oxidative stress. The increased expression of eNOS may suggest an intrinsic production of NO without signs of vascular reactivity

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of pneumonectomy on nitric oxide synthase expression and perivascular edema in the remaining lung of rats

Samano

Pazetti

Prado

et al. 2009

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients [3][4][5]. In last time there were many studys to use neoadjuvant hemiotheraphy for IB, IIA and IIB stage also [6][7][8][9][10][11][12]. Many trials have shown that preoperative chemotherapy for lung cancer is feasible but associated with postoperative morbidity and mortality [3,11].…”

Section: Discusionmentioning

confidence: 99%

Early Complications after Lung Resections at Patients Treated For Lung Cancer with and Without Neoadjuvant Hemiotheraphy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Thoracic surgeons must not hasten to dissect such nodes. Martin et al (2001) reported three significant predictors of the postoperative complications: intraoperative blood loss, forced expiratory volume in the first second (percent predicted), and right pneumonectomy. Thus, thoracic surgeon must attempt their utmost to control and minimise intraoperative bleeding.…”

Section: Surgical Problems In the Trimodality Approach And Their Manamentioning

confidence: 99%

“…Trimodality treatment for N2 NSCLC Most of the reports of the usefulness of the trimodality approach for N2 NSCLC are based on the results of phase II or retrospective trials of preoperative chemoradiotherapy (Faber et al, 1989;Rusch et al, 1993;Deutsch et al, 1994;Albain et al, 1995;Choi et al, 1997;Eberhardt et al, 1998;Katakami et al, 1998;Thomas et al, 1999;Doddoli et al, 2001;Martin et al, 2001;Stamatis et al, 2002;Sonett et al, 2004;Cerfolio et al, 2005;Daly et al, 2006). There are some highly promising and encouraging reports of long-term survival rates of around 30%, however, the toxicity is also substantial, usually exceeding that observed with other multimodality therapy.…”

Section: Specific Diseases Stage III N2 Diseasementioning

confidence: 99%

How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

Kunitoh¹,

Suzuki²

2007

Br J Cancer

View full text Add to dashboard Cite

The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor, and present an overview of the principles for optimisation of the risk/benefit. Numerous clinical questions remain, and enrolment of patients into well-designed clinical trials should be encouraged.

show abstract

Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy

Cited by 289 publications

References 18 publications

Effects of pneumonectomy on nitric oxide synthase expression and perivascular edema in the remaining lung of rats

Effects of pneumonectomy on nitric oxide synthase expression and perivascular edema in the remaining lung of rats

Early Complications after Lung Resections at Patients Treated For Lung Cancer with and Without Neoadjuvant Hemiotheraphy

How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

Contact Info

Product

Resources

About